🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 72 of 857 · Phase 3 first, then by program name

  1. Fremanezumab

    Teva Pharma GmbH

    Cluster Headache

    phase 3 small molecule terminated

    1 trial

  2. Fremanezumab, AJOVY 225 mg solution for injection in pre-filled pen

    Lacuna Pharma Pty Ltd

    Episodic and Chronic Migraine

    phase 3 small molecule active

    1 trial

  3. Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  4. Fulvestrant

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  5. Fulvestrant

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  6. Fulvestrant combined with Pyrotinib

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Breast Cancer

    phase 3 small molecule active

    1 trial

  7. Furazidin, vaginal tablets, 5mg, Dalacin 20 mg/g hüvelykrém

    Lacuna Pharma Pty Ltd

    Bacterial vaginosis

    phase 3 small molecule active

    1 trial

  8. Furmonertinib, AFATINIB, OSIMERTINIB, OSIMERTINIB, AFATINIB, AFATINIB

    ArriVent BioPharma

    Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    phase 3 small molecule active

    1 trial

  9. Futibatinib, FULVESTRANT

    Taiho Pharma Netherlands B.V.

    Malignant Solid Tumors

    phase 3 small molecule active

    1 trial

  10. G-Pen

    Universal Integrated

    Insulin Hypoglycemia

    phase 3 small molecule completed

    1 trial

  11. G-Pen

    Xeris Biopharma Holdings

    Insulin Hypoglycemia

    phase 3 small molecule completed

    1 trial

  12. G-Pen (glucagon injection)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 3 small molecule completed

    1 trial

  13. G-SCF

    The First People's Hospital of Lianyungang

    Granulocyte Colony-stimulating Factor

    phase 3 small molecule active

    1 trial

  14. GA 20 mg/mL

    Teva Pharma GmbH

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  15. GA-GCB (velaglucerase alfa)

    Takeda

    Gaucher Disease

    phase 3 mab completed

    1 trial

  16. GABITRIL (tiagabine hydrochloride; CEP-6671)

    Teva Pharma GmbH

    General Anxiety Disorder

    phase 3 small molecule completed

    1 trial

  17. GALLIUM (68GA) CHLORIDE, TILMANOCEPT

    Disc Medicine

    Endometrial cancer, uterine cancer

    phase 3 small molecule active

    1 trial

  18. GALLIUM (68GA) CHLORIDE, TILMANOCEPT

    Disc Medicine

    Carcinoma of the parotid gland

    phase 3 small molecule active

    1 trial

  19. GALLIUM (68GA) GOZETOTIDE , Zr-DFO-girentuximab, Gallium (68Ga) PSMA-11 (gozetotide) prepared using PSMA-11 Sterile Cold Kit

    Disc Medicine

    Metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  20. GB-0895

    Generate Biomedicines

    Severe Asthma

    phase 3 small molecule active

    2 trials

  21. GC1107

    Green Valley (Shanghai) Pharmaceuticals Co.,

    Bacterial Infections

    phase 3 mab completed

    1 trial

  22. GC4419 90mg

    Galera Therapeutics

    Oral Mucositis

    phase 3 small molecule completed

    1 trial

  23. GCSF

    Hospital Authority, Hong Kong

    End Stage Liver Disease

    phase 3 small molecule active

    1 trial

  24. GEMCI-cell® 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Gemcitabine 1 g Powder for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Carbomedac® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusio

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Unresectable or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources